|
Molecular properties generated using the CDK |
No information available. |
Summary of Clinical Use ![]() |
A Phase 2 clinical trial assessing serabelisib (which has variably been known as INK-1117, MLN1117 and TAK-117) with docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC; NCT02393209) was terminated due to a lack of efficacy of this drug combination. Various Phase 1 and 2 trials with different drug combinations and in different tumour types are ongoing as of October 2018. Click here to link to ClinicalTrials.gov's full list of serabelisib trials. |